BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma

References

• Friend C, Scher W, Holland JG, et al. Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci U S A. 1971;68(2):378–382.
   Google Scholar
• Reuben RC, Wife RL, Breslow R, et al. A new group of potent inducers of differentiation in murine erythroleukemia cells. Proc Natl Acad Sci U S A. 1976;73(3):862–866.
   Google Scholar
• Richon VM, Webb Y, Merger R, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A. 1996;93(12):5705–5708.
   Google Scholar
• Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007;25(1):84–90.
   Google Scholar
• Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A. 1998;95(6):3003–3007.
   Google Scholar
• Nilsson LM, Green LC, Veppil Muralidharan S, et al. Cancer differentiation agent hexamethylene bisacetamide was likely the first BET bromodomain inhibitor in clinical trials. Cancer Res. 2016. DOI:10.1158/0008-5472.CAN-15-2721
   Google Scholar
• Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067–1073..
   Google Scholar
• Nicodeme E, Jeffrey KL, Schaefer U, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468(7327):1119–1123..
   Google Scholar
• Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478(7370):529–533..
   Google Scholar
• Delmore JE, Issa G, Lemieux M, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904–917..
   Google Scholar
• Bhadury J, Nilsson LM, Muralidharan SV, et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci U S A. 2014;111(26):E2721–30.
   Google Scholar
• Lockwood WW, Zejnullahu K, Bradner JE, et al. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A. 2012;109(47):19408–19413.
   Google Scholar
• Shirsat NV, Kayal JJ, Shaikh S, et al. Growth inhibition and differentiation of C6 glioma cells on treatment with hmba. Cell Biol Int. 2001;25(7):621–627.
   Google Scholar
• Li XN, Du ZW, Huang Q. Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells. J Neurosurg. 1996;84(5):831–838.
   Google Scholar
• Cheng Z, Gong Y, Ma Y, et al. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res. 2013;19(7):1748–1759.
   Google Scholar
• Berenguer-Daize C, Astorgues-Xerri L, Odore E, et al. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. Int J Cancer. 2016;139(9):2047–2055.
   Google Scholar
• Rowinsky EK, Ettinger DS, Grochow LB, et al. Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer. J Clin Oncol. 1986;4(12):1835–1844.
   Google Scholar
• Ward FT, Kelley JA, Roth JS, et al. Phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube. Cancer Res. 1991;51(7):1803–1810.
   Google Scholar
• Young CW, Fanucchi MP, Declan Walsh T, et al. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals. Cancer Res. 1988;48(24 Pt 1):7304–7309.
   Google Scholar
• Melloni E, Pontremoli S, Damiani G, et al. Vincristine-resistant erythroleukemia cell line has marked increased sensitivity to hexamethylenebisacetamide-induced differentiation. Proc Natl Acad Sci U S A. 1988;85(11):3835–3839.
   Google Scholar
• Vaidhyanathan S, Mittapalli RK, Sarkaria JN, et al. Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases. Drug Metab Dispos. 2014;42(8):1292–1300.
   Google Scholar
• Einarsdottir BO, Karlsson J, Söderberg EMV, et al. A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma. Cell Death Dis. 2018;9(8):810..
   Google Scholar
• Zawistowski JS, Bevill SM, Goulet DR, et al. Enhancer remodeling during adaptive bypass to mek inhibition is attenuated by pharmacologic targeting of the P-TEFb complex. Cancer Discov. 2017;7(3):302–321..
   Google Scholar
• Daniel P, Filiz G, Brown DV, et al. Selective CREB-dependent cyclin expression mediated by the PI3K and MAPK pathways supports glioma cell proliferation. Oncogenesis. 2014;3:e108.
   Google Scholar
• Daniel PM, Filiz G, Brown DV, et al. PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein. Neuro Oncol. 2018;20(10):1344–1355.
   Google Scholar
• Tan X, Wang S, Yang B, et al. The CREB-miR-9 negative feedback minicircuitry coordinates the migration and proliferation of glioma cells. PLoS One. 2012;7(11):e49570.
   Google Scholar
• Tan X, Wang S, Zhu L, et al. cAMP response element-binding protein promotes gliomagenesis by modulating the expression of oncogenic microRNA-23a. Proc Natl Acad Sci U S A. 2012;109(39):15805–15810.
   Google Scholar
• Amorim S, Stathis A, Gleeson M, et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 2016;3(4):e196–204..
   Google Scholar
• Piha-Paul SA, Sachdev JC, Barve M, et al. First-in-human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory solid tumors. Clin Cancer Res. 2019;25(21):6309–6319..
   Google Scholar
• Postel-Vinay S, Herbschleb K, Massard C, et al. First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity. Eur J Cancer. 2019;109:103–110.
   Google Scholar
• De Raedt T, Beert E, Pasmant E, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014;514(7521):247–251..
   Google Scholar
• Jing Y, Zhang Z, Ma P, et al. MAPK blockade for effective treatment of ovarian cancer. Oncotarget. 2016;7(3):2545–2554.
   Google Scholar
• Ma Y, Wang L, Neitzel LR, et al. The MAPK pathway regulates intrinsic resistance to BET inhibitors in colorectal cancer. Clin Cancer Res. 2017;23(8):2027–2037.
   Google Scholar
• Echevarria-Vargas IM, Reyes-Uribe PI, Guterres AN, et al. Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med. 2018;10(5). DOI:10.15252/emmm.201708446.
   Google Scholar
• Wyce A, Matteo JJ, Foley SW, et al. MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers. Oncogenesis. 2018;7(4):35..
   Google Scholar
• Jespersen H, Lindberg MF, Donia M, et al. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Nat Commun. 2017;8(1):707.
   Google Scholar
• Ny L, Rizzo LY, Belgrano V, et al. Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models. Ann Oncol. 2020;31(2):266–273.
   Google Scholar